# Cytarabine and UCN-01 in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Myelodysplastic Syndrome

> **NCT00004263** · PHASE1 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 16 (actual)

## Conditions studied

- Leukemia
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** 7-hydroxystaurosporine (UCN-01)
- **DRUG:** Cytarabine (Ara-C)

## Key facts

- **NCT ID:** NCT00004263
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-12
- **Primary completion:** 2007-01
- **Final completion:** 2007-01
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2012-07-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00004263

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00004263, "Cytarabine and UCN-01 in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00004263. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*